Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 123

References for PMC Articles for PubMed (Select 21606405)

1.

Cinaciguat, a soluble guanylate cyclase activator, unloads the heart but also causes hypotension in acute decompensated heart failure.

Erdmann E, Semigran MJ, Nieminen MS, Gheorghiade M, Agrawal R, Mitrovic V, Mebazaa A.

Eur Heart J. 2013 Jan;34(1):57-67. doi: 10.1093/eurheartj/ehs196. Epub 2012 Jul 9.

2.

Pulmonary and systemic vasodilator responses to the soluble guanylyl cyclase activator, BAY 60-2770, are not dependent on endogenous nitric oxide or reduced heme.

Pankey EA, Bhartiya M, Badejo AM Jr, Haider U, Stasch JP, Murthy SN, Nossaman BD, Kadowitz PJ.

Am J Physiol Heart Circ Physiol. 2011 Mar;300(3):H792-802. doi: 10.1152/ajpheart.00953.2010. Epub 2011 Jan 7.

3.

Dependence of Golgi apparatus integrity on nitric oxide in vascular cells: implications in pulmonary arterial hypertension.

Lee JE, Patel K, Almodóvar S, Tuder RM, Flores SC, Sehgal PB.

Am J Physiol Heart Circ Physiol. 2011 Apr;300(4):H1141-58. doi: 10.1152/ajpheart.00767.2010. Epub 2011 Jan 7.

4.

Long-term oral treatment with BAY 41-2272 ameliorates impaired corpus cavernosum relaxations in a nitric oxide-deficient rat model.

Claudino MA, da Silva FH, Mónica FZ, Rojas-Moscoso JA, De Nucci G, Antunes E.

BJU Int. 2011 Jul;108(1):116-22. doi: 10.1111/j.1464-410X.2010.09776.x. Epub 2010 Oct 15.

PMID:
20950311
5.

Pulmonary hypertension with left-sided heart disease.

Guazzi M, Arena R.

Nat Rev Cardiol. 2010 Nov;7(11):648-59. doi: 10.1038/nrcardio.2010.144. Epub 2010 Oct 5. Review.

PMID:
20924360
6.

BAY 41-2272 inhibits the development of chronic hypoxic pulmonary hypertension in rats.

Thorsen LB, Eskildsen-Helmond Y, Zibrandtsen H, Stasch JP, Simonsen U, Laursen BE.

Eur J Pharmacol. 2010 Nov 25;647(1-3):147-54. doi: 10.1016/j.ejphar.2010.08.032. Epub 2010 Sep 7.

PMID:
20828552
7.

Riociguat (BAY 63-2521) and warfarin: a pharmacodynamic and pharmacokinetic interaction study.

Frey R, Mück W, Kirschbaum N, Krätzschmar J, Weimann G, Wensing G.

J Clin Pharmacol. 2011 Jul;51(7):1051-60. doi: 10.1177/0091270010378119. Epub 2010 Aug 27.

PMID:
20801938
8.

Cinaciguat, a soluble guanylate cyclase activator for the potential treatment of acute heart failure.

Tamargo J, Duarte J, Caballero R, Delpón E.

Curr Opin Investig Drugs. 2010 Sep;11(9):1039-47.

PMID:
20730699
9.

Pulmonary and systemic vasodilator responses to the soluble guanylyl cyclase stimulator, BAY 41-8543, are modulated by nitric oxide.

Badejo AM Jr, Nossaman VE, Pankey EA, Bhartiya M, Kannadka CB, Murthy SN, Nossaman BD, Kadowitz PJ.

Am J Physiol Heart Circ Physiol. 2010 Oct;299(4):H1153-9. doi: 10.1152/ajpheart.01101.2009. Epub 2010 Jul 16.

10.

Nitric oxide-independent stimulation of soluble guanylate cyclase reduces organ damage in experimental low-renin and high-renin models.

Sharkovska Y, Kalk P, Lawrenz B, Godes M, Hoffmann LS, Wellkisch K, Geschka S, Relle K, Hocher B, Stasch JP.

J Hypertens. 2010 Aug;28(8):1666-75. doi: 10.1097/HJH.0b013e32833b558c.

PMID:
20613628
11.

Guanylyl cyclase activator ataciguat improves vascular function and reduces platelet activation in heart failure.

Schäfer A, Fraccarollo D, Werner L, Bauersachs J.

Pharmacol Res. 2010 Nov;62(5):432-8. doi: 10.1016/j.phrs.2010.06.008. Epub 2010 Jun 22.

PMID:
20600916
12.

Pre-conditioning with the soluble guanylate cyclase activator Cinaciguat reduces ischaemia-reperfusion injury after cardiopulmonary bypass.

Radovits T, Korkmaz S, Miesel-Gröschel C, Seidel B, Stasch JP, Merkely B, Karck M, Szabó G.

Eur J Cardiothorac Surg. 2011 Feb;39(2):248-55. doi: 10.1016/j.ejcts.2010.05.025. Epub 2010 Jun 29.

PMID:
20591683
13.

Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study.

Ghofrani HA, Hoeper MM, Halank M, Meyer FJ, Staehler G, Behr J, Ewert R, Weimann G, Grimminger F.

Eur Respir J. 2010 Oct;36(4):792-9. doi: 10.1183/09031936.00182909. Epub 2010 Jun 7.

14.

Structure of cinaciguat (BAY 58-2667) bound to Nostoc H-NOX domain reveals insights into heme-mimetic activation of the soluble guanylyl cyclase.

Martin F, Baskaran P, Ma X, Dunten PW, Schaefer M, Stasch JP, Beuve A, van den Akker F.

J Biol Chem. 2010 Jul 16;285(29):22651-7. doi: 10.1074/jbc.M110.111559. Epub 2010 May 12.

15.

Emerging drugs for pulmonary hypertension.

Girgis RE.

Expert Opin Emerg Drugs. 2010 Mar;15(1):71-85. doi: 10.1517/14728210903551271. Review.

PMID:
20095920
16.

Pharmacological activation of soluble guanylate cyclase protects the heart against ischemic injury.

Korkmaz S, Radovits T, Barnucz E, Hirschberg K, Neugebauer P, Loganathan S, Veres G, Páli S, Seidel B, Zöllner S, Karck M, Szabó G.

Circulation. 2009 Aug 25;120(8):677-86. doi: 10.1161/CIRCULATIONAHA.109.870774. Epub 2009 Aug 10.

17.

Soluble guanylate cyclase agonists inhibit expression and procoagulant activity of tissue factor.

Sovershaev MA, Egorina EM, Hansen JB, Østerud B, Pacher P, Stasch JP, Evgenov OV.

Arterioscler Thromb Vasc Biol. 2009 Oct;29(10):1578-86. doi: 10.1161/ATVBAHA.109.192690. Epub 2009 Jul 10.

18.

Role of guanylate cyclase modulators in decompensated heart failure.

Mitrovic V, Hernandez AF, Meyer M, Gheorghiade M.

Heart Fail Rev. 2009 Dec;14(4):309-19. doi: 10.1007/s10741-009-9149-7. Review.

PMID:
19568931
19.

Diagnosis, assessment, and treatment of non-pulmonary arterial hypertension pulmonary hypertension.

Hoeper MM, Barberà JA, Channick RN, Hassoun PM, Lang IM, Manes A, Martinez FJ, Naeije R, Olschewski H, Pepke-Zaba J, Redfield MM, Robbins IM, Souza R, Torbicki A, McGoon M.

J Am Coll Cardiol. 2009 Jun 30;54(1 Suppl):S85-96. doi: 10.1016/j.jacc.2009.04.008. Review.

20.

Updated evidence-based treatment algorithm in pulmonary arterial hypertension.

Barst RJ, Gibbs JS, Ghofrani HA, Hoeper MM, McLaughlin VV, Rubin LJ, Sitbon O, Tapson VF, Galiè N.

J Am Coll Cardiol. 2009 Jun 30;54(1 Suppl):S78-84. doi: 10.1016/j.jacc.2009.04.017. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk